Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L)
|ClinicalTrials.gov Identifier: NCT01279798|
Recruitment Status : No longer available
First Posted : January 19, 2011
Last Update Posted : March 1, 2011
|Condition or disease||Intervention/treatment|
|Non-small Cell Lung Cancer||Biological: Lucanix® (belagenpumatucel-L)|
The primary objective of this study is to increase the overall survival of the study subjects by providing expanded access to Lucanix. Overall survival and progression-free survivals will be compared with historical controls.
The secondary objectives of this study are:
- Evaluate the best overall tumor response.
- Evaluate progression-free survival (PFS).
- Evaluate treatment toxicity.
|Study Type :||Expanded Access|
|Official Title:||Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L) in Advanced Non-small Cell Lung Cancer.|
Biological: Lucanix® (belagenpumatucel-L)
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01279798
|United States, California|
|Innovative Research Center of California|
|San Diego, California, United States, 92103|